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Abstract 
Background: Long chain omega-3 polyunsaturated fatty acids (LCn3PUFAs) may improve 
cardiovascular health and depression. This study investigated the relationships between erythrocyte 
membrane LCn3PUFA status, depression and angina symptoms in patients with heart disease. 
Methods: We recruited 91 patients (65 males and 26 females, mean age 59.2 ± 10.3 years) with heart 
disease and depressive symptoms (Center for Epidemiological Studies Depression Scale, CES-D ≥ 16) 
and low fish/fish oil intakes. The Omega-3 Index (EPA+DHA) of erythrocyte membranes (as a 
percentage of total fatty acids) was assessed by gas chromatography. Depression status was measured 
by both self -report and clinician-report scales; CES-D and the Hamilton depression scale (HAM-D). 
Angina symptoms were measured using the Seattle Angina Questionnaire and the Canadian 
Cardiovascular Society Classification for Angina Pectoris. 
Results: The mean Omega-3 Index was 4.8 ± 1.0% (±SD). Depression scores measured by CES-D and 
HAM-D were 29.2 ± 8.8 (moderate to severe) and 11.0 ± 5.7 (mild) (arbitrary units) respectively 
reflecting a different perception of depressive symptoms between patients and clinicians. Angina 
status was inversely associated with depressions scores (r > -0.26, P < 0.03). There were no significant 
relationships between individual LCn3PUFA or the Omega-3 Index and either the depression scores or 
the angina symptoms.  
Conclusion: Worse angina status was associated with worse depression, but the Omega-3 Index was 
not associated with symptoms of depression or angina in patients with heart disease.  
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Introduction 
In patients with cardiovascular disease (CVD), depression is common and associated with high 
mortality rates [1]. Depression is also an independent risk factor for the development of coronary heart 
disease [2]. A number of pathophysiological factors including endothelial dysfunction, altered platelet 
activity and aggregation, inflammation and autonomic nervous system dysfunction have been 
suggested to link depression with adverse cardiac outcomes [3]. Also, as a major manifestation of 
coronary heart disease (CHD), angina may be one of the possible mediators in the relationship 
between CHD and depression. Depression can augment perceived pain [4] thus the sensation of angina 
may be increased in patients with depression [5]. 
The long chain omega-3 polyunsaturated fatty acids (LCn3PUFAs) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid) (DHA) may improve cardiovascular health and depression via a number of 
mechanisms. Cardiovascular benefits of LCn3PUFAs include lowering blood pressure and resting 
heart rate, improving heart rate variability and vascular endothelial function, decreasing serum 
triglycerides levels, inhibiting inflammation, platelet aggregation and new plaque development [6, 7]. 
The exact mechanism by which LCn3PUFAs may influence depression remains unclear. However, 
DHA is highly concentrated in the retina, brain and nervous system [8], and plays important roles in 
the structure (neuronal membranes) and function (neurotransmission and receptor function) of 
neurons, the growth of neural cells, and the gene expression in the brain [9].  
The role of LCn3PUFAs in improving endothelial function in the brain might optimise the auto-
regulation of cerebral perfusion and blood brain barrier integrity, thus enhancing mental health by 
adequate oxygen and nutrition supply to brain regions [10]. LCn3PUFAs may also increase levels of 
monoaminergic neurotransmitters in the brain [11], and inhibit inflammation that is associated with 
depression [9]. The mechanisms underlying depression are complex and, while there is some evidence 
linking change to cerebrovascular structure and function with depression [12], other evidence suggests 
that inflammatory changes are central [13]. Changes in inflammatory markers following 
supplementation with LCn3PUFAs have been proposed to be central to improvements seen in vascular 
function in adults with metabolic syndrome [14]. Furthermore, low levels of omega 3s have been 
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associated with cerebral small vessel disease in acute ischemic stroke patients [15]. In a meta-analysis 
of prospective cohort studies and randomised controlled trials (RCT), Chowdhury et al [16] found 
moderate inverse associations between fish consumption and incidence of cerebrovascular disease. 
Interestingly, LCn3PUFAs measured as circulating biomarkers in observational studies or given as 
supplements in primary and secondary prevention trials were not associated with cerebrovascular 
disease, suggesting that the positive effects may be due to the wide variety of nutrients in fish or may 
reflect a healthier dietary pattern or higher socioeconomic status. 
 
Despite evidence of mechanisms for how LCn3PUFAs may reduce the risk of developing CHD and 
depression, whether supplementation is beneficial for either condition remains controversial. 
Epidemiological studies have reported low LCn3PUFA status in patients with CHD compared with 
healthy age and gender matched controls [17]. Furthermore, The PREDIMED study reported [18] 
protection from cardiac mortality with LCn3PUFAs. Hazard ratios for meeting the recommended intake 
of LCn3PUAFS (500mg/day) (n=5452, 75.7%) were, 0.61 (95% CI 0.39-0.96) for fatal cardiovascular 
disease, and 0.54 (95% CI 0.29-0.99) for fatal coronary heart disease. Evidence from large RCTs have 
shown beneficial effects of LCn3PUFAs on CHD mortality. Supplementation with LCn3PUFAs as part 
of cardiovascular disease management have been found to reduce the risk of non-fatal coronary events 
in Japanese hypercholesterolaemic patients (JELIS study), reduce the risk of death, non-fatal myocardial 
infarction and stroke in Italian patients with a history of myocardial infarctions (original GISSI-P) [19] 
and improve survival for patients with chronic heart failure (GISSI-HF) [20]. However, recent meta-
analyses have generated conflicting results, with one concluding that supplementation with LCn3PUFA 
may not reduce the incidence of coronary events but may improve the odds of survival [21] while 
another concluded that there was no significant reduction in mortality from supplementation with 
LCn3PUFAs.[22]. Differences may be due to inclusion or exclusion of individual studies; however, it 
is currently suggested that there is neither a beneficial nor adverse effect of LCn3PUFA supplementation 
for primary or secondary prevention of coronary heart disease  [23]. 
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A major manifestation of CHD is the presence of angina symptoms. There is limited research 
investigating angina symptoms and LCn3PUFA and what few studies there are have provided mixed 
results. A small RCT of 20 patients with stable angina reported benefits associated with fish oil 
supplementation [24] but two other studies found no benefits [25, 26]. Understanding relationships 
between angina symptoms, depression and omega 3 status may help to explain these mixed findings.  
Epidemiological studies have also reported low levels of LCn3PUFAs in people with depression [27]. 
Cross-sectional studies have also reported that depressed patients with heart disease have significantly 
lower blood levels of DHA compared with non-depressed patients [28-30]. There are mixed 
conclusions from meta-analyses as to whether omega 3 supplements are beneficial for reducing the 
risk of depression [31, 32]. A meta-analysis of clinical trials of treatment with LCn3PUFAs for 
depression concluded that the use of these supplements is effective in patients with a diagnosis of 
Major Depressive Disorders (MDD) and in depressive patients without a diagnosis of MDD.[33] 
 
This study investigated associations of LCn3PUFA status, with (a) depression severity and (b) angina 
symptoms in patients with cardiac disease and depression who were low fish consumers. It was 
hypothesised that in patients with heart disease, LCn3PUFA status would be inversely associated with 
depression severity and angina symptoms. 
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Methods 
Study design 
The present study represents a secondary analysis of baseline data collected in a randomized placebo-
controlled trial that evaluated the effects of supplementation with long chain omega-3 polyunsaturated 
fatty acids on depression scores in patients with heart disease. The RCT was approved by the Human 
Research Ethics Committees at the Queen Elizabeth Hospital (Ethics Reference Number: 2008104) 
and the University of South Australia (Ethics Reference Number: P223/08) and registered on the 
Australian New Zealand Clinical Trials Registry (ACTRN12608000598381). Each participant 
provided written informed consent before enrolment. 
Patients 
Patient inclusion criteria comprised: (1) angiographically-documented coronary artery disease (defined 
as >50% stenosis in an epicardial coronary artery on selective coronary angiography [34]) or systolic 
heart failure (heart failure admission and an ejection fraction < 40%), (2) co-morbid clinically relevant 
depression (determined by a score of greater than or equal to 16 on the Center for Epidemiological 
Studies Depression Scale (CES-D) [35]), and (3) able to complete questionnaires in written English. 
Exclusion criteria were the consumption of more than one fish meal per week or the regular use of fish 
oil supplements (containing more than 300mg EPA + DHA per day). 
Procedure 
Participants were recruited in 2009-2013 during hospital admission or outpatient visits and by mail-out 
invitations from two public hospitals that service the North-Western Adelaide suburbs (population 
approximately 550,000) and by newspaper advertisements.  
 
Demographic data, cardiovascular risk factors, current diagnoses, and medication history were 
obtained by patient interview and case note extraction. If eligible, participants completed a self-
reported depression assessment and a clinician completed an assessment of depression. Height and 
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body mass were used to calculate body mass index (BMI) and fasting venous blood samples were 
collected from which LCn3PUFA status was measured in erythrocyte membranes. 
Quantification of Angina Symptoms 
Angina status was measured by the Seattle Angina Questionnaire (SAQ) [36] and the Canadian 
Cardiovascular Society Classification for Angina Pectoris (CCSA) [37]. The SAQ assessed four 
domains of interest for this study (angina frequency, physical limitation, quality of life and treatment 
satisfaction). Scores of each subscale ranges from 0 (lowest level) to 100 (highest level). The CCSA 
measured severity of angina symptoms across 4 grades from best (I) to worst (IV), (i.e. the reverse 
order to the SAQ instrument). Both have good reliability and validity [36, 38]. 
Quantification of Depressive Symptoms 
Self-reported depressive symptoms were assessed using the CES-D, a 20 item scale designed to 
measure the level of depressive symptoms during the past week [39 ]. Standard threshold scores were 
not depressed (CES-D < 16), mild depression (CES-D = 16-26) and moderate to severe depression 
(CES-D > 26). 
Clinician-rated depression was assessed using HAM-D, a 21 item rating scale assessing a patient’s 
current level of depression [40]. Levels of depression were classified as normal (0 – 7), mild 
depression (8 –16), moderate depression (17 – 23), and severe depression (≥ 24) [41]. 
Determination of fatty acids 
Fasting venous blood samples were collected in 10ml tubes containing ethylenediaminetetraacetic 
acid. Erythrocytes were separated from plasma via centrifugation at 1780 g for ten minutes at 4℃, 
washed with isotonic saline and stored at -80℃. After thawing, fatty acid contents of erythrocytes 
were determined using previous published modifications of Lepage and Roy’s technique [42]. 
Samples were analyzed by a gas chromatography (GC2010, Shimadzu) and fatty acids were identified 
and quantified against a reference standard (GLC-463, Nu-Chek Prep Inc. Elysian, MN, USA). 
Individual fatty acid contents were reported as percentages of total fatty acids in erythrocytes. The 
Omega-3 index was calculated as the sum of erythrocyte membrane eicosapenatenoic acid (EPA) and 
docosahexaenoic acid (DHA). 
9 
 
Statistical Analysis 
Statistical analysis was performed using SPSS Statistics for windows, version 21.0 (IBM Corp, 
Armonk, NY). Data were checked for normality and variables presented as mean and standard 
deviation (mean ± SD). Student’s t-tests and 1-way ANOVAs were performed to test for differences 
between groups based on depression severity and Spearman Rank and Pearson correlations were used 
where relevant to determine the relationships between LCn3PUFA status, angina status and depression 
scores. P < 0.05 was considered statistically significant. 
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Results 
Patients 
3817 patients were invited to participate and 340 patients were screened. 110 patients agreed to 
participate, but 18 withdrew before the baseline interview. Thus 92 patients took part in the study and 
91 had complete baseline data (Figure 1). 
Patient characteristics are provided in Table 1. The majority of patients (78%) had coronary heart 
disease, with 51% having stable angina. Most had very mild angina status (reflected by levels equal or 
greater than 50 (arbitrary units) on the five subscales of the SAQ) (data not shown). This was 
consistent with the measurement of angina severity by the CCSA with the majority of patients (88.8%) 
being classified into grade I and grade II indicating either no or slight limitation of ordinary activity 
related to angina (data not shown). Of note, 43% of patients were taking at least one antidepressant 
medication. 
Depression status 
Depression data are provided in Table 2. As assessed by the CES-D, more than half (53/91) of patients 
had moderate to severe depression and when measured by HAM-D, about one third were not 
depressed (28/91), 47/91 had mild depression and 16/91 had moderate to severe depression. There was 
no difference between men and women in depression status.  
Long chain omega-3 polyunsaturated fatty acid status 
The mean erythrocyte membrane levels of EPA, DPA and DHA were 0.8 ± 0.3%, 2.4 ± 0.4% and 4.0 
± 0.9% respectively. The mean Omega-3 Index was 4.8 ± 1.0% (ranging from 3.1 to 7.6%) and the 
mean erythrocyte membrane level of total LCn3PUFAs was 7.2 ± 1.1%. Stratifying the Omega-3 
Index by the severity of depression indicated that patients with higher depression scores, measured by 
either CES-D or HAM-D, tended to have a higher Omega-3 Index (Table 3).  
Associations between membrane fatty acids, angina symptoms and depressive symptoms 
There were no significant relationships between depression measures and any of the individual 
LCn3PUFAs (data not shown) or between the Omega-3 Index and either self-reported (CES-D; r = 
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0.152, P = 0.150) or clinician-rated (HAM-D; r = 0.098, P = 0.357) depression. No significantly 
different associations were observed when data were split into those taking or not taking 
antidepressant medication. 
There were no significant associations between Omega-3 Index and angina status measured by either 
SAQ or CCSA (Table 4). There were weak to moderate negative correlations between depression 
scores and angina status, indicating that better angina status was associated with less depression  
(Table 4). 
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Discussion 
The principal finding of this study was that while worse symptoms of angina were associated with 
greater severity of depression the Omega-3 Index was not associated with either. Thus, our hypotheses 
were not supported.  
The relationships between blood levels of LCn3PUFAs and depression remain controversial in the 
literature. Many studies have found lower LCn3PUFA levels in erythrocyte membranes [28], total 
serum [29], plasma [43] and plasma phospholipids [30, 44] in depressed patients and inverse 
relationships between these LCn3PUFA biomarkers and depression status, while others have found no 
such relationships [42, 45-47]. These discrepancies may be due to differing demographic 
characteristics of the samples evaluated (including severity of depressive symptoms), type of 
cardiovascular disease, the method of depression measurement and the component of blood extracted 
for the assessment of LCn3PUFA content. Whilst the content of LCn3PUFAs in blood samples is a 
useful and accessible biomarker of LCn3PUFA status, the fraction of blood used for analysis is 
important. Erythrocyte membrane content is considered to be the most reliable, biologically relevant, 
and long-term marker of dietary LCn3PUFA intake, with the Omega-3 Index reflecting the erythrocyte 
membrane content of EPA and DHA and having shown to be inversely associated with risk for CHD 
mortality [48]. 
The mean Omega-3 Index in the present study was 4.8 ± 1.0%. This is comparable with levels 
reported in other Australian studies, where values ranged from 3.97 to 5.78% [42, 49] in healthy 
controls. Milte et al reported  similar omega-3 levels in people with mild cognitive impairment (MCI) 
and age matched healthy controls (HC) (mean ± SEM ; MCI 5.49 ± 0.13% vs HC 5.78 ± 0.17%)  [42]. 
By comparison the mean Omega-3 Index in an American population with acute coronary syndrome 
and depression was 2.9%,  compared with 3.3% in those with acute coronary syndrome but without 
depression [28]. The Omega-3 index was also found to be lower in a German population with major 
depressive disorder (3.9%),  compared to healthy controls (5.1%) [27]. It may be that omega-3 status 
only influences depression below a threshold Omega-3 Index of ~ 4-5%, and thus the omega-3 status 
of patients in the present study was too high to see any effect. Dietary differences across countries, 
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and/or the way in which depression has been diagnosed, may account for some of the differences in 
findings between studies. 
Rates of depression vary widely across the world [50] and the intake of long chain omega 3 varies 
between countries [51], with several including Australia [52] and the USA [53] reporting that 
population intakes are below the recommended levels. A recent study in the USA examined plasma 
LCn3PUFA concentrations as a biomarker assessment of LCn3PUFA status in a nationally 
representative cohort (NHANES) and reported that nearly the whole population had levels below those 
associated with cardiovascular protection [54]. Whilst the plasma levels differ from the Omega-3 
Index, these findings are nevertheless supportive. 
Different dietary patterns including pro-inflammatory diets  have been linked to increased risk of 
depression  [55], [56] although a recent meta-analysis highlighted the variability in findings [57]. The 
association between fish consumption specifically and risk of depression was recently reviewed with 
results from a  meta-analysis concluding that high fish consumption was associated with reduced risk 
of depression, the pooled risk ratio of depression for the highest versus lowest consumption of fish 
being 0.83 (95% CI 0.74 to 0.93) [58]. However, when studies were separated by continent, not all 
followed the same pattern; there were significant associations in studies conducted in Europe but not 
in those conducted in North America, South America, Asia and Oceania. This heterogeneity may 
result from differences in fish type, fish preservation and cooking styles or from differences in 
methods used to report intake. Cultural and socioeconomic differences across countries in these 
continents are also an important consideration when considering diet patterns and stimuli of depressive 
symptoms [59]. 
 
Another difference between the findings of this report and previous studies is that the majority of 
previous studies have compared depressed and non-depressed groups of patients rather than assessing 
the relationship between LCn3PUFA status and severity of depressive symptoms within a sample with 
depression. It might be expected to be more difficult to demonstrate a relationship between 
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LCn3PUFAs and depression within a more homogenous population than between two different 
populations, and in particular in a population that for the most part was not severely depressed. In two 
studies reporting no association between blood levels of LCn3PUFAs and depression status [45, 46] 
the authors argued that a significant association may be evident only in clinical or severe levels of 
depression. This is partially supported by a study in a Dutch community population (n = 241), which 
did not find an association between levels of LCn3PUFAs in plasma phospholipids and depression 
status in the full sample but found a strong inverse relationship (r = -0.465, P = 0.005) in those 
participants who reported clinically relevant depressive symptoms (CES-D ≥ 16, n = 35) [60]. A meta-
analysis of trials conducted in populations with major depression or trials conducted in other 
populations found that beneficial effects of LCn3PUFAs on depressive symptoms were only evident in 
populations with major depression [61]. The patients in the present study were screened for depression 
status by CES-D (CES-D ≥ 16), which was considered as clinically relevant level of depressive 
symptoms. However, when the patients were assessed using the clinician rated tool, almost one third   
(28 of 91) did not reach the clinically relevant level (HAM-D ≥ 8). Moreover, more than half of the 
patients (53) had moderate to severe depressive symptoms measured by CES-D whereas less than one 
fifth  (16) had moderate to severe depressive symptoms when they were assessed using the HAM-D 
instrument (Table 2). HAM-D may be a more sensitive and specific tool than CES-D and truly reflect 
the depression status of these patients. Thus, the lack of a relationship between LCn3PUFA status and 
depression in the present study may have been due to only a small proportion of the sample having 
clinically relevant or severe depression. Future studies should aim to recruit populations with a 
broader range of depressive symptoms to explore this further. Nevertheless, despite the low ratings of 
depression, we found that worse angina status was associated with higher depression scores. These 
findings are consistent with previous studies which have reported that patients with higher depression 
scores (measured by CES-D) suffered more frequent angina (measured by SAQ) [5]. However, there 
were no associations between angina status and the Omega-3 Index. 
A limitation of the present study that might have contributed to the absence of a significant 
relationship between LCn3PUFA status and depression or angina symptoms is insufficient statistical 
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power. Using the correlation coefficient obtained from testing the association between CES-D 
depression scores and the Omega 3 Index (r = 0.152), a post hoc power analysis [62] found that 266 
participants would be required to detect a significant relationship. However, despite not being 
statistically significant, because the coefficient (r = 0.152) only explains approximately 2% of the 
variance in depression scores (CES-D), it is unlikely to be clinically meaningful. Common factors 
associated with LCn3PUFAs and depression are age, gender, race, education, hypertension, diabetes, 
BMI, medications and smoking status [28]. These variables may influence the relationship between 
LCn3PUFAs and depression, which might not only reduce the statistical power, but also confound the 
effects of LCn3PUFAs on depression. Some of these variables were recorded (Table 1), however 
given the small sample size in the present study, no analyses controlling for these potential 
confounders were performed. Increasing the size of the sample and performing analyses controlling 
for these factors may have assisted in finding a significant relationship between blood levels of 
LCn3PUFAs and depression status. 
A strength of this study was the determination of omega-3 status by measuring the Omega-3 Index. 
However a limitation was the narrow distribution of the Omega-3 index in the study population.  The 
minimal variability of the Omega-3 Index in this group may have limited the ability to detect a 
relationship between the Omega 3 index and depression. It is possible that associations may exist 
between omega 3 status and depression when a population with a broader range of omega 3 intakes are 
considered. Future studies should also look at relationships between changes in omega 3 erythrocyte 
content and changes in depression in controlled supplementation studies. 
Conclusion 
In summary, the Omega-3 Index was not associated with the depression scores measured by HAM-D 
or CES-D in depressed cardiac patients who have low fish / omega-3 intake. The absence of 
significant relationships may be due to the small sample size or relatively low severity of depression in 
the present sample. The relationship between LCn3PUFAs and depression in patients with heart 
disease remains unclear. 
16 
 
Acknowledgments 
This study was supported by a joint initiative between Beyond Blue and The National Heart 
Foundation of Australia - CVD and Depression Strategic Research Program.   
17 
 
References 
1. Chauvet-Gélinier J-C, Trojak B, Vergès-Patois B, Cottin Y, Bonin B. Review on depression 
and coronary heart disease. Arch Cardiovasc Dis. 2013;106(2):103-110. 
2. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression 
and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry. 
2007;22(7):613-626. 
3. Huffman JC, Celano CM, Beach SR, Motiwala SR, Januzzi JL. Depression and cardiac 
disease: epidemiology, mechanisms, and diagnosis. Cardiovasc Psychiatry Neurol. 2013;2013:695925. 
4. Schweinhardt P, Kalk N, Wartolowska K, Chessell I, Wordsworth P, Tracey I. Investigation 
into the neural correlates of emotional augmentation of clinical pain. NeuroImage. 2008;40(2):759-
766. 
5. Arnold SV, Spertus JA, Ciechanowski PS, Soine LA, Jordan-Keith K, Caldwell JH, et al. 
Psychosocial modulators of angina response to myocardial ischemia. Circulation. 2009;120(2):126-
133. 
6. Kris-Etherton PM, Harris WS, Appel LJ, Committee ftN. Fish consumption, fish oil, omega-3 
fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-2757. 
7. Colquhoun D, Ferreira-Jardim A, Udell T, Eden B, the Nutrition and Metabolism Committee 
of the Heart Foundation. Review of evidence:  Fish, fish oils, n-3 polyunsaturated fatty acids and 
cardiovascular health. Online: National Heart Foundation of Australia; 2008. Available from: 
http://www.heartfoundation.org.au/SiteCollectionDocuments/Fish-FishOils-revie-of-evidence.pdf. 
8. Salem N, Jr., Litman B, Kim H-y, Gawrisch K. Mechanisms of action of docosahexaenoic 
acid in the nervous system. Lipids. 2001;36(9):945-959. 
9. Sinclair AJ, Begg D, Mathai M, Weisinger RS. Omega 3 fatty acids and the brain: Review of 
studies in depression. Asia-Pac J Clin Nutr. 2007;16 (Suppl 1):391-397. 
10. Sinn N, Howe PRC. Mental health benefits of omega-3 fatty acids may be mediated by 
improvements in cerebral vascular function. Biosci Hypotheses. 2008;1(2):103-108. 
11. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet A-M, Besnard J-C, et al. 
Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr. 
1998;128(12):2512-2519. 
12. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. The American journal of 
psychiatry. 2015:appiajp201515030363. 
13. Spalletta G, Bossu P, Ciaramella A, Bria P, Caltagirone C, Robinson RG. The etiology of 
poststroke depression: a review of the literature and a new hypothesis involving inflammatory 
cytokines. Mol Psychiatry. 2006;11(11):984-991. 
14. Tousoulis D, Plastiras A, Siasos G, Oikonomou E, Verveniotis A, Kokkou E, et al. Omega-3 
PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in 
adults with metabolic syndrome. Atherosclerosis. 2014;232(1):10-16. 
15. Song TJ, Chang Y, Shin MJ, Heo JH, Kim YJ. Low levels of plasma omega 3-polyunsaturated 
fatty acids are associated with cerebral small vessel diseases in acute ischemic stroke patients. 
Nutrition research (New York, NY). 2015;35(5):368-374. 
16. Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, et al. Association 
between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: 
systematic review and meta-analysis. BMJ (Clinical research ed). 2012;345:e6698. 
17. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA. EPA and DHA in blood cell 
membranes from acute coronary syndrome patients and controls. Atherosclerosis. 2008;197(2):821-
828. 
18 
 
18. Sala-Vila A, Guasch-Ferre M, Hu FB, Sanchez-Tainta A, Bullo M, Serra-Mir M, et al. Dietary 
alpha-Linolenic Acid, Marine omega-3 Fatty Acids, and Mortality in a Population With High Fish 
Consumption: Findings From the PREvencion con DIeta MEDiterranea (PREDIMED) Study. Journal 
of the American Heart Association. 2016;5(1). 
19. Marchioli R, Marfisi RM, Borrelli G, Chieffo C, Franzosi MG, Levantesi G, et al. Efficacy of 
n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial 
infarction: insights from the GISSI-Prevenzione trial. Journal of cardiovascular medicine 
(Hagerstown, Md). 2007;8 Suppl 1:S34-37. 
20. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 
polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, 
double-blind, placebo-controlled trial. Lancet (London, England). 2008;372(9645):1223-1230. 
21. Wen YT, Dai JH, Gao Q. Effects of Omega-3 fatty acid on major cardiovascular events and 
mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. 
Nutrition, metabolism, and cardiovascular diseases : NMCD. 2014;24(5):470-475. 
22. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty 
acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-
analysis. Jama. 2012;308(10):1024-1033. 
23. Nestel P, Clifton P, Colquhoun D, Noakes M, Mori TA, Sullivan D, et al. Indications for 
Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular 
Disease. Heart, lung & circulation. 2015;24(8):769-779. 
24. Salachas A, Papadopoulos C, Sakadamis G, Styliadis J, Voudris V, Oakley D, et al. Effects of 
a low-dose fish oil concentrate on angina, exercise tolerance time, serum triglycerides, and platelet 
function. Angiology. 1994;45(12):1023-1031. 
25. Solomon SA, Cartwright I, Pockley G, Greaves M, Preston FE, Ramsay LE, et al. A placebo-
controlled, double-blind study of eicosapentaenoic acid-rich fish oil in patients with stable angina 
pectoris. Curr Med Res Opin. 1990;12(1):1-11. 
26. Vacek JL, Harris WS, Haffey K. Short-term effects of omega-3 fatty acids on exercise stress 
test parameters, angina and lipoproteins. Biomed Pharmacother. 1989;43(5):375-379. 
27. Baghai TC, Varallo-Bedarida G, Born C, Hafner S, Schule C, Eser D, et al. Major depressive 
disorder is associated with cardiovascular risk factors and low Omega-3 Index. J Clin Psychiat. 
2011;72(9):1242-1247. 
28. Amin AA, Menon RA, Reid KJ, Harris WS, Spertus JA. Acute coronary syndrome patients 
with depression have low blood cell membrane omega-3 fatty acid levels. Psychosom Med. 
2008;70(8):856-862. 
29. Frasure-Smith N, Lesperance F, Julien P. Major depression is associated with lower omega-3 
fatty acid levels in patients with recent acute coronary syndromes. Biol Psychiat. 2004;55(9):891-896. 
30. Parker G, Heruc G, Hilton T, Olley A, Brotchie H, Hadzi-Pavlovic D, et al. Low levels of 
docosahexaenoic acid identified in acute coronary syndrome patients with depression. Psychiat Res. 
2006;141(3):279-286. 
31. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic 
review and meta-analysis. Mol Psychiatry. 2012;17(12):1272-1282. 
32. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic 
acid (EPA) in clinical trials in depression. J Clin Psychiat. 2011;72(12):1577-1584. 
33. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, et al. Role of omega-3 
fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized 
clinical trials. PloS one. 2014;9(5):e96905. 
19 
 
34. Harris PJ, Behar VS, Conley MJ, Harrell FE, Jr., Lee KL, Peter RH, et al. The prognostic 
significance of 50% coronary stenosis in medically treated patients with coronary artery disease. 
Circulation. 1980;62(2):240-248. 
35. Zich JM, Attkisson CC, Greenfield TK. Screening for depression in primary care clinics: The 
CES-D and the BDI. Intl J Psychiat Med. 1990;20(3):259-277. 
36. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. 
Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for 
coronary artery disease. J Am Coll Cardiol. 1995;25(2):333-341. 
37. Selzer A, Cohn K. Functional classification of cardiac disease: a critique. Am J Cardiol. 
1972;30(3):306-308. 
38. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of 
systems for assessing cardiovascular functional class: Advantages of a new specific activity scale. 
Circulation. 1981;64(6):1227-1234. 
39. Radloff LS. The CES-D scale: A self-report depression scale for research in the general 
population. Appl Psych Meas. 1977;1(3):385-401. 
40. Hamilton M. A rating scale for depression. J Neurol Neurosur Ps. 1960;23:56-62. 
41. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on 
the Hamilton Depression Rating Scale. J Affect Disord. 2013;150(2):384-388. 
42. Milte CM, Sinn N, Street SJ, Buckley JD, Coates AM, Howe PRC. Erythrocyte 
polyunsaturated fatty acid status, memory, cognition and mood in older adults with mild cognitive 
impairment and healthy controls. Prostaglandins Leukot Essent Fatty Acids. 2011;84(5-6):153-161. 
43. Feart C, Peuchant E, Letenneur L, Samieri C, Montagnier D, Fourrier-Reglat A, et al. Plasma 
eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the 
elderly: Data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr. 2008;87(5):1156-
1162. 
44. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid 
composition and depression are associated in the elderly: The Rotterdam Study. Am J Clin Nutr. 
2003;78(1):40-46. 
45. Appleton KM, Gunnell D, Peters TJ, Ness AR, Kessler D, Rogers PJ. No clear evidence of an 
association between plasma concentrations of n-3 long-chain polyunsaturated fatty acids and 
depressed mood in a non-clinical population. Prostaglandins Leukot Essent Fatty Acids. 
2008;78(6):337-342. 
46. Jadoon A, Chiu C-C, McDermott L, Cunningham P, Frangou S, Chang C-J, et al. Associations 
of polyunsaturated fatty acids with residual depression or anxiety in older people with major 
depression. J Affect Disord. 2012;136(3):918-925. 
47. Ruusunen A, Virtanen JK, Lehto SM, Tolmunen T, Kauhanen J, Voutilainen S. Serum 
polyunsaturated fatty acids are not associated with the risk of severe depression in middle-aged 
Finnish men: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study. Eur J Nutr. 2011;50(2):89-
96. 
48. Harris WS, von Schacky C. The omega-3 index: A new risk factor for death from coronary 
heart disease? Prev Med. 2004;39(1):212-220. 
49. Milte CM, Coates AM, Buckley JD, Hill AM, Howe PRC. Dose-dependent effects of 
docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels. Br J 
Nutr. 2008;99(5):1083-1088. 
50. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in 
the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological 
literature. Psychological Medicine. 2013;43(3):471-481. 
20 
 
51. Harika RK, Eilander A, Alssema M, Osendarp SJ, Zock PL. Intake of fatty acids in general 
populations worldwide does not meet dietary recommendations to prevent coronary heart disease: a 
systematic review of data from 40 countries. Annals of nutrition & metabolism. 2013;63(3):229-238. 
52. Meyer B. Australians are not Meeting the Recommended Intakes for Omega-3 Long Chain 
Polyunsaturated Fatty Acids: Results of an Analysis from the 2011–2012 National Nutrition and 
Physical Activity Survey. Nutrients. 2016;8(3):111. 
53. Papanikolaou Y, Brooks J, Reider C, Fulgoni VL, 3rd. U.S. adults are not meeting 
recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational 
data from NHANES 2003-2008. Nutrition journal. 2014;13:31. 
54. Murphy RA, Yu EA, Ciappio ED, Mehta S, McBurney MI. Suboptimal Plasma Long Chain n-
3 Concentrations are Common among Adults in the United States, NHANES 2003-2004. Nutrients. 
2015;7(12):10282-10289. 
55. Khosravi M, Sotoudeh G, Majdzadeh R, Nejati S, Darabi S, Raisi F, et al. Healthy and 
Unhealthy Dietary Patterns Are Related to Depression: A Case-Control Study. Psychiatry 
investigation. 2015;12(4):434-442. 
56. Sanchez-Villegas A, Ruiz-Canela M, de la Fuente-Arrillaga C, Gea A, Shivappa N, Hebert JR, 
et al. Dietary inflammatory index, cardiometabolic conditions and depression in the Seguimiento 
Universidad de Navarra cohort study. Br J Nutr. 2015;114(9):1471-1479. 
57. Rahe C, Unrath M, Berger K. Dietary patterns and the risk of depression in adults: a 
systematic review of observational studies. Eur J Nutr. 2014;53(4):997-1013. 
58. Li F, Liu X, Zhang D. Fish consumption and risk of depression: a meta-analysis. Journal of 
epidemiology and community health. 2016;70(3):299-304. 
59. Jacka FN, Cherbuin N, Anstey KJ, Butterworth P. Dietary patterns and depressive symptoms 
over time: examining the relationships with socioeconomic position, health behaviours and 
cardiovascular risk. PloS one. 2014;9(1):e87657. 
60. Schiepers OJ, de Groot RH, Jolles J, van Boxtel MP. Plasma phospholipid fatty acid status 
and depressive symptoms: Association only present in the clinical range. J Affect Disord. 2009;118(1-
3):209-214. 
61. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, et al. Effects of n–3 
long-chain polyunsaturated fatty acids on depressed mood: Systematic review of published trials. Am 
J Clin Nutr. 2006;84(6):1308-1316. 
62. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: 
Tests for correlation and regression analyses. Behav Res Methods. 2009;41:1146-1160. 
 
 
21 
 
Figure 1: The Consort diagram showing patient recruitment for this cross-sectional analysis. CES-D = 
Epidemiological Studies Depression Scale 
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Table 1: Characteristics of the Patients (n = 91) 
Variables Mean ± SD or n (%) 
Age (Years) 59.2±10.3 
BMI (kg/m2) + 30.5±5.9 
Gender  
     Male 65 (71%) 
     Female 26 (29%) 
Type of Heart Disease  
     Coronary Heart Disease 71 (78%) 
     Heart Failure 20 (22%) 
     Stable Angina 46 (51%) 
Smoking Status  
     Non-smokers 20 (22%) 
     Current Smoker 25 (27%) 
     Past Smoker 46 (51%) 
Hypertension 50 (55%) 
Type 2 Diabetes 30 (33%) 
Family History of Premature cardiovascular disease  
     Yes 45 (49%) 
     No 41 (45%) 
     Unknown 5 (6%) 
Medication History  
     Aspirin 66 (75%) 
     Clopidogrel 32 (35%) 
     Nitrates 42 (46%) 
     Calcium Channel Blockers 47 (52%) 
     Beta Blockers 31 (34%) 
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     ACEI 46 (51%) 
     ARB 15 (16%) 
     Diuretics 32 (35%) 
     Digoxin 13 (14%) 
     Antiarrhythmic agents 6 (7%) 
     Statins 68 (75%) 
     Fibrates 4 (4%) 
     Benzodiazepines 18 (20%) 
     SSRI 19 (21%) 
     Tricyclic antidepressant 9 (10%) 
     Other Antidepressant 18 (20%) 
ACEI = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin Receptor Blocker, BMI = 
Body Mass Index, SD = Standard deviation, SSRI = Selective Serotonin Re-uptake Inhibitor,+ n = 90 
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Table 2: Depression status of patients (n = 91) 
Variable n Mean ± SD 
CES-D  29.2 ± 8.8 
  Mild (≥ 16 and ≤ 26) 38 21.1 ± 3.4 
  Moderate to severe (> 26) 53 35.1 ± 6.7 
HAM-D  11.0 ± 5.7 
  None (0 – 7) 28 5.2 ± 1.4 
  Mild (8 – 16) 47 11.2 ± 2.6 
  Moderate (17 – 23) 13 19.7 ± 1.8 
  Severe (≥ 24) 3 25.3 ± 1.2 
CES-D = Center for Epidemiological Studies Depression Scale, HAM-D = Hamilton Depression 
Scale, SD = Standard Deviation 
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Table 3: The Omega-3 Index stratified by depression scores (n =91) 
Depression scores 
n Omega-3 Index  
 (Mean ± SD) P value 
CES-D    
  Mild (≥ 16 and ≤ 26) 38 4.6 ± 1.0 
0.085 
  Moderate to severe (> 26) 53 4.9 ± 1.0 
HAM-D    
  None (0 – 7) 28 4.6 ± 0.8 
0.817 
  Mild (8 – 16) 47 4.8 ± 1.1 
  Moderate (17 – 23) 13 4.9 ± 1.0 
  Severe (≥ 24) 3 5.6 ± 0.5 
CES-D = Center for Epidemiological Studies Depression Scale, HAM-D = Hamilton Depression 
Scale, SD = Standard deviation 
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Table 4: Correlations between the Omega-3 Index, depression status and angina study 
 
Omega-3 Index HAM-D CES-D 
r P value r P value r P value 
SAQ       
     Angina Frequency -0.005 0.963 -0.313 0.003 -0.273 0.009 
     Physical 
Limitation 
0.167 0.149 -0.374 
0.001 -0.262 
0.022 
     Disease 
Perception 
-0.003 0.976 -0.364 
0.000 -0.371 
0.000 
     Treatment 
Satisfaction 
0.139 0.192 -0.338 
0.001 -0.285 
0.007 
CCSA* -0.002 0.986 0.308 0.003 0.257 0.015 
CCSA = Canadian Cardiovascular Society Classification for Angina Pectoris, CES-D = Center for 
Epidemiological Studies Depression Scale, HAM-D = Hamilton Depression Scale, SAQ = Seattle 
Angina Questionnaire. *Spearman's rank-order correlation coefficient (rho)reported for relationships 
with CCSA. Statistically significant at p<0.05. 
